IN2014CN04558A - - Google Patents

Info

Publication number
IN2014CN04558A
IN2014CN04558A IN4558CHN2014A IN2014CN04558A IN 2014CN04558 A IN2014CN04558 A IN 2014CN04558A IN 4558CHN2014 A IN4558CHN2014 A IN 4558CHN2014A IN 2014CN04558 A IN2014CN04558 A IN 2014CN04558A
Authority
IN
India
Prior art keywords
compound
formula
salts
salt
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce D Dorsey
Keith S Learn
Emma L Morris
Gregory R Ott
Jonathan R Roffey
Christelle N Soudy
Jason C Wagner
Original Assignee
Cancer Rec Tech Ltd
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd, Cephalon Inc filed Critical Cancer Rec Tech Ltd
Publication of IN2014CN04558A publication Critical patent/IN2014CN04558A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4558CHN2014 2011-11-23 2012-11-19 IN2014CN04558A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563310P 2011-11-23 2011-11-23
PCT/US2012/065831 WO2013078126A1 (fr) 2011-11-23 2012-11-19 Inhibiteurs de type thiénopyrimidine de protéines kinases c atypiques

Publications (1)

Publication Number Publication Date
IN2014CN04558A true IN2014CN04558A (fr) 2015-09-18

Family

ID=47295200

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4558CHN2014 IN2014CN04558A (fr) 2011-11-23 2012-11-19

Country Status (12)

Country Link
US (3) US9604994B2 (fr)
EP (2) EP2782917B1 (fr)
JP (1) JP6206926B2 (fr)
CN (1) CN104053661B (fr)
AU (2) AU2012340869B2 (fr)
CA (1) CA2855446C (fr)
ES (1) ES2575143T3 (fr)
HK (1) HK1202529A1 (fr)
IL (1) IL232559B (fr)
IN (1) IN2014CN04558A (fr)
MX (1) MX355088B (fr)
WO (1) WO2013078126A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097013A1 (fr) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
TWI589579B (zh) * 2012-01-10 2017-07-01 林伯士艾瑞斯公司 Irak抑制劑及其用途
WO2014011902A1 (fr) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
US9067948B2 (en) 2012-07-11 2015-06-30 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
CA2890911A1 (fr) 2013-01-10 2014-07-17 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisations
WO2015048281A1 (fr) 2013-09-27 2015-04-02 Nimbus Iris, Inc. Inhibiteurs d'irak et leurs utilisation
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
KR20180075228A (ko) * 2016-12-26 2018-07-04 한미약품 주식회사 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
WO2019119206A1 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
CN108658999B (zh) * 2018-04-24 2021-02-05 温州大学 2-苯基杂环并[2,3-d]嘧啶-4(3H)-酮类化合物的合成方法
EP3632908A1 (fr) 2018-10-02 2020-04-08 Inventiva Inhibiteurs de l'interaction yap / taz-tead et leur utilisation dans le traitement du cancer
MX2021005875A (es) * 2018-11-20 2021-09-23 Univ Georgetown Composiciones y métodos para el tratamiento de trastornos neurodegenerativos, miodegenerativos y de almacenamiento lisosómico.
EP3725788A1 (fr) * 2019-04-15 2020-10-21 Bayer AG Nouveaux composés azole d'aminoalkyle substitués par hétéroaryle en tant que pesticides
CN116410205A (zh) * 2021-12-29 2023-07-11 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并***并噁嗪类化合物的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
TW564247B (en) 1999-04-08 2003-12-01 Akzo Nobel Nv Bicyclic heteraromatic compound
US6506762B1 (en) 1999-09-30 2003-01-14 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CN100345830C (zh) 2000-04-27 2007-10-31 安斯泰来制药有限公司 稠合杂芳基衍生物
KR20030034232A (ko) 2000-09-29 2003-05-01 닛뽕소다 가부시키가이샤 티에노피리미딘 화합물 및 그 염 및 제조방법
WO2003022214A2 (fr) 2001-09-06 2003-03-20 Millennium Pharmaceuticals, Inc. Composes a base de piperazine et d'homopiperazine
EP1474147B1 (fr) 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Composes a base de pyrimidine utiles en tant qu'inhibiteurs des gsk-3
WO2004017950A2 (fr) 2002-08-22 2004-03-04 Piramed Limited Inhibiteurs de phosphatidylinositol 3,5-biphosphate en tant qu'agents antiviraux
AR044743A1 (es) 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
WO2005069865A2 (fr) 2004-01-13 2005-08-04 Ambit Biosciences Corporation Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
WO2005123087A2 (fr) 2004-06-15 2005-12-29 Merck & Co., Inc. Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante
WO2006093518A2 (fr) 2004-06-25 2006-09-08 Apath, Llc Composes thienyle pour traiter des etats pathologiques lies a un virus
WO2006010568A2 (fr) 2004-07-23 2006-02-02 Curacyte Discovery Gmbh Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine-2,4(1 h,3h)-diones et pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3h)-ones substituees, thieno[2,3-d:4,5-d']dipyrimidine-2,4(1 h,3h)-diones et thieno[2,3-d:4,5-d']dipyrimidin-4(3h)-ones substituees, pyrido[3',2':4,5]furo[3,2-d]pyrimidine-2,4(1 h,3h)-diones et pyrido[3',2':4,5]furo[3,2-
DE102005013621A1 (de) 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
EP2041139B1 (fr) 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Composés pharmaceutiques
WO2008037607A1 (fr) 2006-09-25 2008-04-03 Basf Se Composés hétérocycliques à teneur en groupe carbonyle et leur utilisation pour lutter contre des champignons phytopathogènes
RU2470936C2 (ru) * 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
JP2011521941A (ja) 2008-05-30 2011-07-28 ミトロジクス Ant−リガンド分子および生物学的アプリケ−ション
KR101430424B1 (ko) * 2009-01-08 2014-08-14 쿠리스 인코퍼레이션 아연 결합 모이어티를 갖는 포스포이노시티드 3-키나제 억제제
KR101675614B1 (ko) 2009-10-29 2016-11-11 벡투라 리미티드 Jak3 키나아제 저해제로서의 n―함유 헤테로아릴 유도체
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療

Also Published As

Publication number Publication date
AU2017203725A1 (en) 2017-06-22
EP3048106B1 (fr) 2019-11-06
EP2782917A1 (fr) 2014-10-01
US9604994B2 (en) 2017-03-28
JP2014533728A (ja) 2014-12-15
HK1202529A1 (zh) 2015-10-02
AU2012340869B2 (en) 2017-03-02
US10954251B2 (en) 2021-03-23
IL232559B (en) 2018-04-30
MX355088B (es) 2018-04-04
IL232559A0 (en) 2014-06-30
CA2855446C (fr) 2021-04-20
MX2014006233A (es) 2014-10-17
NZ625447A (en) 2015-09-25
CA2855446A1 (fr) 2013-05-30
CN104053661A (zh) 2014-09-17
CN104053661B (zh) 2018-06-19
EP3048106A1 (fr) 2016-07-27
AU2012340869A1 (en) 2014-06-19
EP2782917B1 (fr) 2016-03-02
US20170158706A1 (en) 2017-06-08
JP6206926B2 (ja) 2017-10-04
US10183950B2 (en) 2019-01-22
US20190106433A1 (en) 2019-04-11
AU2017203725B2 (en) 2019-02-28
WO2013078126A1 (fr) 2013-05-30
ES2575143T3 (es) 2016-06-24
US20140323435A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
IN2014CN04558A (fr)
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
PH12014501653A1 (en) Metalloenzyme inhibitor compounds
PH12015501316A1 (en) Heterocyclic compound
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
UA110338C2 (en) Chemical compounds
PH12014502733A1 (en) Neprilysin inhibitors
MY172924A (en) Neprilysin inhibitors
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MX339455B (es) Inhibidores de pirimidina y topoisomerasa iv.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
NZ707308A (en) Malononitrile compounds for controlling animal pests
IN2013MU03015A (fr)
MX2015007568A (es) Compuestos de malononitrilo para controlar plagas de animales.
EP2807191B8 (fr) Méthodes de traitement de la douleur par le biais de l'inhibition de l'activité du vgf
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1